In vivo and in vitro effects of simvastatin on inflammatory markers in pre-dialysis patients

Authors:
  • SPSabrina Paoletti
    Sabrina Paoletti
  • EMEmanuela Mantuano
    Emanuela Mantuano
  • GMGiovanni Manca-Rizza
    Giovanni Manca-Rizza
  • CFCristina Filippi
    Cristina Filippi
  • SSSamuele Santi
    Samuele Santi
  • DTDaniele Taccola
    Daniele Taccola
  • CDCarlo Donadio
    Carlo Donadio
  • GTGianfranco Tramonti
    Gianfranco Tramonti
  • MIMaurizio Innocenti
    Maurizio Innocenti
  • GCGiuseppe Casto
    Giuseppe Casto
  • CCCristina Consani
    Cristina Consani

Abstract
Background. The beneficial effects of statins in reducing cardiovascular events have been attributed predominantly to their lipid-lowering effects, recent studies suggest that these effects might be due to their anti-inflammatory properties. We here investigate the in vivo and in vitro effects of simvastatin on cytokine production in pre-dialysis chronic renal failure patients. Methods. Our clinical study has been designed as a randomized double-blind placebo controlled study. A total of 55 chronic kidney disease (CKD) patients at stages 3 and 4 (mean creatinine clearance 45 ml/min, range 15–60) were randomly assigned to receive simvastatin 40 mg/day or placebo, added to their ongoing treatment, for 6 months. Blood samples were obtained at baseline, and after 3 and 6 months of observation for the determination of lipids, inflammatory markers and renal function. For the in vitro studies, the effect of increasing doses of simvastatin on cytokine production [namely interleukin (IL)-6 and IL-8] in human cultured monocytes from 10 healthy subjects (HS) and 15 CKD patients stimulated by lipopolysaccharide (LPS) was investigated. Results. A significant reduction in total cholesterol from 221±44 mg/dl to 184±41 mg/dl (3 months) and to 186±39 mg/dl (6 months) (PPP = 0.03) at 6 months (PP = 0.001) at 6 months was also observed. No significant reduction in inflammatory markers [CRP from 5.1 mg/l (IQR 1.9) to 5.4 mg/l (IQR 1.3) (P = NS) at 6 months] or plasma lipids [LDL-cholesterol from 127±32 mg/dl to 131±21 mg/dl (6 months)] was observed in the 27 patients of the placebo group. In the in vitro studies, the average value for cell-associated IL-6 and IL-8 was higher in CKD (155±95 pg/ml monocytes for IL-6 and 722±921 pg/ml monocytes for IL-8) vs HS (137±87 pg/ml monocytes and 186±125 pg/ml monocytes) (PPConclusions. These results indicate that simvastatin in commonly used doses has an in vitro and in vivo anti-inflammatory effect in CKD patients, and may play an important role in counteracting the mechanisms involved on the pathogenesis of cardiovascular disease.

This publication has 20 references indexed in Scilit: